Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Sanofi

Thumbnail
March 03, 2021

A busy year ahead for Parkinson’s disease

As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.

Thumbnail
March 01, 2021

Early data boost Aslan, but don’t ignore the red flags

Article image
Vantage logo
March 01, 2021

US FDA approval tracker February

Article image
Vantage logo
February 18, 2021

Lilly takes a chance on Rip kinase inhibition

Article image
Vantage logo
February 17, 2021

Lynparza’s Olympia win could broaden breast cancer use

The Parp inhibitor registers an unexpected clinical win in the adjuvant setting, but more convincing data might still be needed.

Article image
Vantage logo
February 16, 2021

Cytovia turns to Cellectis for gene editing

Article image
Vantage logo
February 12, 2021

Amicus fail dents Pompe pipeline

Amicus follows Sanofi with disappointing pivotal Pompe data, casting further doubt on approvals.

Article image
Vantage logo
February 11, 2021

Astra places its bet in oestrogen receptor degradation

Article image
Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

The company talks up sasanlimab, whose subcutaneous delivery might challenge at least some PD-(L)1 laggards.

Article image
Vantage logo
February 02, 2021

Tezepelumab’s non-eosinophilic edge emerges

Article image
Vantage logo
February 01, 2021

Covid-19 vaccine pipeline builds as Clover and Dynavax push on

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.